Follitropin alfa biosimilar - Qilu Pharmaceutical
Alternative Names: QL-1012; QL1012DLatest Information Update: 25 Mar 2025
At a glance
- Originator Qilu Pharmaceutical
- Class Follicle stimulating hormones; Infertility therapies; Peptide fragments; Pituitary gonadotropins; Recombinant fusion proteins; Recombinant proteins
- Mechanism of Action Follicle stimulating hormone replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Female infertility
Most Recent Events
- 11 Mar 2025 Qilu Pharmaceutical plans a phase I bioequivalence trial for Female infertility (In volunteers) (SC, Injection) in May 2025 (NCT06864793)
- 14 Dec 2021 No development reported - Phase-III for Female infertility in China (SC) (Qilu Pharmaceutical pipeline, December 2021)
- 17 Oct 2019 Qilu Pharmaceutical completes a phase III trial in Female infertility in China (SC) (NCT05149924)